Please login to the form below
COVID-19 vaccines
This page shows the latest COVID-19 vaccines news and features for those working in and with pharma, biotech and healthcare.
Pfizer and BioNTech sign $3.2bn COVID-19 vaccine supply agreement with US government
The companies will supply 105 million doses, which may include adult Omicron-adapted COVID-19 vaccines, subject to FDA authorisation. ... COVID-19 vaccines, subject to authorisation from the US Food and Drug Administration (FDA).
Latest news
-
Moderna to launch Innovation and Technology Center in the UK
UK. Throughout the COVID-19 pandemic, Moderna worked with governments, healthcare professionals and other key stakeholders to help combat the virus and future pathogens. ... The company, with the support of the UK government, plans to use the site to
-
EU governments pressure manufacturers to renegotiate contracts for COVID-19 vaccines
Poland has over 30 million COVID-19 vaccines in stock and, under existing agreements, would need to buy another 70 million, according to a Polish diplomat in a discussion with Reuters. ... Leading suppliers of COVID-19 vaccines, Pfizer and Moderna, have
-
Will that be cash or charge?
But when people ask me about India’s decision to charge its own citizens for doses of COVID-19 vaccines (including booster doses), I reluctantly point to the academic literature for ... The private ‘cost’ of COVID-19 vaccines is also very low. We
-
Sanofi and GSK share positive data for two COVID-19 booster vaccine trials
Sanofi and GSK have jointly developed a next-generation COVID-19 booster vaccine candidate, based on Sanofi’s recombinant Beta variant antigen and combined with GSK’s pandemic adjuvant. ... Thomas Triomphe, executive vice president, Sanofi Vaccines,
-
UK trial of fourth vaccine dose shows increased protection against COVID-19
According to findings from a UK trial, COV-BOOST, fourth doses of COVID-19 vaccines have shown an increase in protection against the virus, especially in those over the age of ... will take into consideration whether new sub-variants are spreading, and
More from news
Approximately 5 fully matching, plus 201 partially matching documents found.
Latest Intelligence
-
Behaviour change – a maze of decisions influenced by personal habits, experiences and intentions
The scale of the challenge and the glacial slowness of behaviour change response has neutralised many past efforts, but the rapid development of COVID-19 vaccines combined with regulatory flex and ... relative to COVID-19 (make it attractive) and use
-
To avoid making mistakes when applying behavioural insights in healthcare, we need to understand why people do what they do
mandates laid out in the Sustainable Development Goals, and the WHO is using behavioural science to help increase acceptance and uptake of COVID-19 vaccines globally. ... While this may solve the short-term problem, COVID-19 vaccines, like flu vaccines,
-
Trust in the new vaccines – the vital role of healthcare communications
Vaccine hesitancy, of course, existed long before COVID-19, but resistance to the routine immunisation of children has largely been associated with the ‘anti-vax’ movement. ... Lack of confidence in the new COVID-19 vaccines has been reported in
-
The new reality of building a corporate brand in pharma
The global pandemic has heightened everyone’s awareness of healthcare. An interesting thing has happened during the race to produce COVID-19 vaccines in that perceptions of the pharma sector have ... The impact of COVID-19 on pharma. And as mentioned
-
Now that COVID-19 vaccines have been approved, it’s our turn, healthcare communicators
Now it’s our turn. As healthcare communicators, our attitudes, along with the quality and accessibility of our work, will undoubtedly affect the uptake of approved COVID-19 vaccines. ... 4. Expect the goalposts to change. It is my fervent hope that the
More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.
Latest from PMHub
-
Could femtech be the answer to the gender health gap?
25. 5. It's bridging the gender data gap. As we mentioned in our recent blog ‘Why the COVID-19 vaccines are a women’s health issue’, there is a concerning ... MobiHealthNews. Published August 12, 2021. Accessed November 4, 2021. Nearly two million
-
How scientific storytelling can help Pharma cut through the noise
This again can be particularly powerful for comparisons of risk – such as the risk of adverse side effects from Covid-19 vaccines.
-
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving ... COVID-19 has prompted an interest in microbiology,
-
WHITE PAPER: From bench to bedside in one year - how the race for a COVID-19 vaccine will change the future of drug development
2. Andrews N, et al.Impact of COVID-19 Vaccines on Mortality in England.London; 2021. ... https://www.health.harvard.edu/blog/why-are-mrna-vaccines-so-exciting-2020121021599. Accessed June 10, 2021. 7. Understanding Viral Vector COVID-19 Vaccines.
-
Vaccine hesitancy eBook
Today, all eyes are on vaccines. At its high, the US administered 3.4 million doses of the COVID-19 vaccines per day, but in April, this number dwindled ... The motivations behind the Arm in Arm campaign, a global campaign designed to encourage
More from PMHub
Approximately 0 fully matching, plus 18 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- NHS App to revolutionise digital health and care with major digital updates by 2023
- A new era for UK-Japanese scientific research relations
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- Sanofi Global Health unveils new nonprofit Impact brand
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- A creative awakening – how pharma is bringing innovation to the patient journey
- Behaviour change – a maze of decisions influenced by personal habits, experiences and intentions
- My journey advancing the science in pulmonary hypertension
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
- Delivering content to fuel omnichannel engagement
PMHub
Porterhouse Medical Group
The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
